Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04483544 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Olaparib in Cervical Cancer Patients
A Phase 2 study, sponsored by Baptist Health South Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04483544 is a Phase 2 study that was terminated before completion, run by Baptist Health South Florida. The registered enrollment target is 8 participants.
The verdict
NCT04483544, a Phase 2 study, was terminated before completion, sponsored by Baptist Health South Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
Interventions
- DRUG pembrolizumab
- DRUG olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04483544
The ClinicalTrials.gov registry entry for NCT04483544 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04483544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04483544 about?
NCT04483544 is a clinical study titled "Pembrolizumab and Olaparib in Cervical Cancer Patients". The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
What is the current status of trial NCT04483544?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-12-03. Estimated completion is 2024-12-12.
What interventions are being tested in trial NCT04483544?
The interventions under investigation include: pembrolizumab (DRUG), olaparib (DRUG).
Who is sponsoring clinical trial NCT04483544?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.